130
Views
2
CrossRef citations to date
0
Altmetric
Original Research

SLCO4A1 is a Prognosis-Associated Biomarker Involved in Neutrophil-Mediated Immunity in Thyroid Cancer

, , &
Pages 9615-9628 | Published online: 11 Dec 2021

References

  • Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578
  • Gao B, Guo L, Luo D, et al. Steroid receptor coactivator-1 interacts with NF-κB to increase the VEGFC level in human thyroid cancer. Biosci Rep. 2018;38:BSR20180394. doi:10.1042/BSR20180394
  • Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
  • Cooper D, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi:10.1089/thy.2009.0110
  • Qi Y, Ji M, Guan H, et al. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J Clin Endocrinol Metab. 2013;98(12):E1909–E1917. doi:10.1210/jc.2013-2583
  • Luster M, Mäder U, Giovanella L, et al. European perspective on the 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Proceedings of an interactive international symposium. Thyroid. 2018;28:722–728. doi:10.1089/thy.2017.0352
  • Shoup M, Stojadinovic A, Nissan A. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197(2):191–197. doi:10.1016/S1072-7515(03)00332-6
  • Mushimiyimana I, Tomas Bosch V, Niskanen H, et al.Genomic landscapes of non-coding RNAs regulating VEGFA and VEGFC expression in endothelial cells. Mol Cell Biol. 2021;41(7):MCB–00594.
  • Tacconi C, Correale C, Gandelli A, et al.Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. Gastroenterology. 2015;148(7):1438–1451.
  • Demei M, XiangXin L, YongPing X, et al. Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer. J Int Med Res. 2013;41(5):1541–1549. doi:10.1177/0300060513493038
  • Razy N, Wan F, Win TT. Expression of vascular endothelial growth factor and its receptors in thyroid nodular hyperplasia and papillary thyroid carcinoma: a tertiary health care centre based study. APJCP. 2019;20(1):277.
  • Yu X-M, Lo C-Y, Chan W-F, Lam K-Y, Leung P, Luk JM. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–8069. doi:10.1158/1078-0432.CCR-05-0646
  • Stieger B, Hagenbuch B. Organic anion-transporting polypeptides. Curr Top Membr. 2014;73(73):205–232.
  • Buxhofer-Ausch V, Secky L, Wlcek K, et al. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. 2013;2013:863539. doi:10.1155/2013/863539
  • Brenner S, Klameth L, Riha J, et al. Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer Lett. 2014;356(2):517–524.
  • Kleberg K, Jensen GM, Christensen DP. Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia. BMC Gastroenterol. 2012;12(1):78. doi:10.1186/1471-230X-12-78
  • Hays A, Apte U, Hagenbuch B. Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res. 2013;30(9):2260. doi:10.1007/s11095-012-0962-7
  • Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633. doi:10.2196/27633
  • Wright JL, Kwon EM, Ostrander EA, et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomark Prev. 2011;20(4):619. doi:10.1158/1055-9965.EPI-10-1023
  • Gu Y, Hu C. Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer. Biofactors. 2019;45(6):902–911. doi:10.1002/biof.1561
  • Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013;20(2):R19–R29. doi:10.1530/ERC-12-0219
  • He LZ, Zeng T-S, Pu L, et al. Thyroid hormones, autoantibodies, ultrasonography, and clinical parameters for predicting thyroid cancer. Int J Endocrinol. 2016;2016:1–11. doi:10.1155/2016/8215834
  • Granot Z. Neutrophils as a therapeutic target in cancer. Front Immunol. 2019;10:1710. doi:10.3389/fimmu.2019.01710